


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
Fanny Astruc et al.
Application No.: 10/767,814
Filing Date: January 30, 2004
Title: INVERT EMULSIONS CONTAINING
DHEA



MAIL STOP AMENDMENT

Group Art Unit: 1617
Examiner: CARLIC K HUYNH
Confirmation No.: 6599

SECOND
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a SECOND Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date October 9, 2007

By: Mary Katherine Baumeister
Mary Katherine Baumeister
Registration No. 26254

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Fanny Astruc et al.

Application No.: 10/767,814

Filed: January 30, 2004

For: INVERT EMULSIONS CONTAINING
DHEA



MAIL STOP AMENDMENT

Group Art Unit: 1617

Examiner: CARLIC K HUYNH

Confirmation No.: 6599

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Applicants request the Examiner's consideration of the documents listed on the accompanying Form PTO-1449.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required.

An Information Disclosure Statement was filed in the above-identified application on July 15, 2005. This IDS was incorrectly identified as the "SECOND" Information Disclosure Statement when it was the FIRST. Therefore, we have identified this IDS correctly as the SECOND. English language counterparts or translations/abstract/statements of relevance were not properly filed in the previous IDS. Therefore, we have re-filed these references along with the appropriate documents.

This Statement, Form PTO-1449 and listed documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

The following comments are offered with regard to the references which are not in English:

JP 60-161912 A is in Japanese. An English translation is not available. An English abstract is provided. The abstract and English-language International Search Report (ISR) serve as brief statements of relevance.

FR 2 777 194 A is in French. No English translation is available. The English-language ISR serves as a brief statement of relevance.

FR 2 803 513 A1 is in French. An English-language counterpart (US 2003/0124084) is cited to serve in place of a translation. Its abstract and the English-language ISR serve as a brief statement of relevance.

EP 0 779 071 B1 is in French. An English-language counterpart (US 5,935,588) is cited to serve as an English translation and its abstract serves as a brief statement of relevance. The EP document also has English-language claims.

WO 01/26618 A2 is in French. A machine-made English translation from the EPO is enclosed. The English abstract and English language search report serve as brief statements of relevance.

WO 98/40074 is in French. An English-language counterpart US 6,620,803 B2 is cited to serve in place of an English translation. The English abstract serves as a brief statement of relevance.

It is respectfully requested that an Examiner-initialed copy of the accompanying Form PTO-1449 be returned to the undersigned.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: October 9, 2007

By:


Mary Katherine Baumeister
Registration No. 26254

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620